NASDAQ:MCRB Seres Therapeutics Q3 2025 Earnings Report $19.70 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$19.27 -0.43 (-2.18%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Seres Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.05Beat/MissN/AOne Year Ago EPSN/ASeres Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$5.88 millionBeat/MissN/AYoY Revenue GrowthN/ASeres Therapeutics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Seres Therapeutics Earnings HeadlinesSeres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic ...October 14 at 11:34 AM | markets.businessinsider.comSeres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell TransplantOctober 14 at 7:00 AM | globenewswire.com$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.October 15 at 2:00 AM | Weiss Ratings (Ad)Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $14.33 Consensus PT from BrokeragesOctober 6, 2025 | americanbankingnews.comSeres Therapeutics price target raised to $22 from $14 at CanaccordSeptember 24, 2025 | msn.comSeres Therapeutics, Inc.: Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend ...September 23, 2025 | finanznachrichten.deSee More Seres Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email. Email Address About Seres TherapeuticsSeres Therapeutics (NASDAQ:MCRB) is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted. Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection. Seres is also advancing SER-287 in ulcerative colitis, SER-401 in combination with immunotherapy for certain cancers, and other preclinical programs targeting metabolic and inflammatory diseases. The company collaborates with strategic partners, including Nestlé Health Science, to support development, manufacturing scale-up and global research efforts. Founded in 2010, Seres went public in 2015 to further accelerate its clinical pipeline. The management team comprises experienced biotech executives, clinicians and scientists with expertise in microbiome research and product development. Seres continues to conduct multi‐center clinical trials across North America and Europe, seeking to bring first‐in‐class microbiome therapies to patients with limited treatment options.View Seres Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings CSX (10/16/2025)Interactive Brokers Group (10/16/2025)Bank of New York Mellon (10/16/2025)American Noble Gas (10/16/2025)Marsh & McLennan Companies (10/16/2025)Charles Schwab (10/16/2025)Travelers Companies (10/16/2025)Taiwan Semiconductor Manufacturing (10/16/2025)U.S. Bancorp (10/16/2025)American Express (10/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
